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Abstract
Although historically considered as junk-DNA, tandemly repeated sequence motifs can affect human phenotype. For
example, variable number tandem repeats (VNTR) with embedded enhancers have been shown to regulate gene
transcription. The post-zygotic variation is the presence of genetically distinct populations of cells in an individual derived
from a single zygote, and this is an understudied aspect of genome biology. We report somatically variable VNTR with
sequence properties of an enhancer, located upstream of IFNAR1. Initially, SNP genotyping of 63 monozygotic twin pairs
and multiple tissues from 21 breast cancer patients suggested a frequent post-zygotic mosaicism. The VNTR displayed a
repeated 32 bp core motif in the center of the repeat, which was flanked by similar variable motifs. A total of 14 alleles were
characterized based on combinations of segments, which showed post-zygotic and inter-individual variation, with up to 6
alleles in a single subject. Somatic variation occurred in ,24% of cases. In this hypervariable region, we found a clustering of
transcription factor binding sites with strongest sequence similarity to mouse Foxg1 transcription factor binding motif. This
study describes a VNTR with sequence properties of an enhancer that displays post-zygotic and inter-individual genetic
variation. This element is within a locus containing four related cytokine receptors: IFNAR2, IL10Rb, IFNAR1 and IFNGR2, and
we hypothesize that it might function in transcriptional regulation of several genes in this cluster. Our findings add another
level of complexity to the variation among VNTR-based enhancers. Further work may unveil the normal function of this
VNTR in transcriptional control and its possible involvement in diseases connected with these receptors, such as
autoimmune conditions and cancer.
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Introduction
The Encyclopedia of DNA Elements (ENCODE) project has
recently characterized regions of transcription, transcription factor
association, and chromatin structure suggesting biochemical
functions for up to 80% of the human genome [1]. Repetitive
DNA sequences with shorter repeat-motifs fall into two main
categories; interspersed repeats and variable number tandem
repeats (VNTR). The interspersed repeats are remnants of
transposons and are more abundant than VNTRs [2]. In VNTRs,
repeat-motifs are positioned right next to each other. They are
called microsatellites, with repeat-motifs ,10 bp, and minisatel-
lites with repeats $10 bp. The VNTRs are sometimes extremely
variable with de novo mutation rates up to 1023 per locus per cell
division and their mutation rates therefore typically exceed
mutation rates of CNVs and SNPs by factor 10 to 100,000 [2].
Although historically considered as part of junk-DNA, VNTRs
can affect human phenotype. For example, disorders such as
Fragile X syndrome [3], spinobulbar muscular atrophy [4], and
Huntington disease [5] have all been associated with specific
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unstable repeat expansions within genes (reviewed in [2,6,7]).
VNTRs outside of genes have also been found to influence gene
expression and phenotype. For instance, it is established that
variants of a repeat in the promoter of the serotonin transporter
(SLC6A4) are associated with expression levels and susceptibility to
anxiety-disorder [8]. Similarly, VNTR variation in the promoter
of nitric oxide synthase 2 (NOS2) alter expression and is associated
with diabetic retinopathy [9]. In these above examples, the
phenotypically important VNTRs were located in promoters, but
gene expression can also be affected by distantly located VNTR-
based enhancers. For example, variable allele length of a 59-
VNTR of the human insulin gene (INS) are associated with gene
expression levels both in vitro and in vivo, and predispose to, among
others, insulin-dependent diabetes mellitus [10,11]. Importantly,
the same VNTR region has also been found to affect the
expression of another gene (IGF2), located downstream relative to
INS [12]. These results provide an important proof of concept by
showing that VNTRs with embedded enhancer properties can
influence expression levels of distantly located genes (reviewed in
[13]).
Structural changes in the genome (such as deletions, duplica-
tions/insertions, translocations, inversions and complex rearrange-
ments) have been identified as a major type of inter-individual
variation [14]. The best studied subset of structural changes,
involving variation in the copy number DNA segments, are
referred to as copy number variation (CNV). The rate of de novo
formation for CNVs has been estimated to exceed the corre-
sponding rate for single nucleotide polymorphisms (SNPs) [15,16].
Analyses of various types of human genetic variation performed
hitherto are dominated by comparisons of different people. Little
attention has been paid so far to analysis of acquired during life-
time differences between somatic cells from different tissues of the
same person (i.e. post-zygotic variation, or mosaicism) [17]. The
definition of post-zygotic variation is the presence of genetically
distinct populations of somatic cells in an individual derived from a
single zygote. The paucity of studies addressing post-zygotic
genetic variation is remarkable, especially in view of the fact that
many common disorders are apparently not a result of inheritance
of defective allele(s) from the parents [18]. Reviews suggest that
post-zygotic mosaicism is understudied and consequently under-
estimated [17,19,20,21,22]. Moreover, predictions indicate that
the somatic variation must be widespread [23,24]. Given the high
de novo mutation rates for chromosomal regions with CNVs and
VNTRs, such loci should also be somatically variable and studies
using monozygotic (MZ) twins, aging human cohorts and
differentiated tissues point towards the importance of this aspect
of human genetics [25,26,27,28].
We describe a somatically variable VNTR with a repeated motif
of 32 bp on chromosome 21q22.11. This VNTR is located in a
region containing four related cytokine receptor genes, namely
IFNAR2, IL10Rb, IFNAR1 and IFNGR2. We show that this locus is
somatically variable using cohorts of monozygotic twins as well as
multiple tissues from single subjects and that it has sequence
properties suggesting it to be an enhancer.
Methods
Cohorts of studied subjects
Blood samples from 63 pairs of monozygotic (MZ) twin pairs
were studied. Of these, 22 MZ pairs were young (age 3–43) [28].
The remaining MZ twins were older than 60 years and derived
from the Swedish Adoption Twin Study of Aging (SATSA) from
the population-based Swedish Twin Registry [28]. Moreover, 21
patients with breast cancer were included, where we studied blood,
primary tumor and normal breast tissue from the same affected
breast.
Ethics Statement
The study is approved by the Regional Research Ethics
Committee in Uppsala. The collections of human samples at all
involved centers (Karolinska Institutet, Sweden; NIH, USA and
Oncology Center, Bydgoszcz, Poland) have been approved by
their respective Research Ethics Committee. Each studied adult
subject has provided written informed consent. Written informed
consent was obtained from the caretakers/guardians on the behalf
of the minors/children that participated in this study.
Illumina SNP genotyping
All samples were genotyped on Illumina 610-array or 660W




nanogram of genomic DNA was genotyped using Illumina-
human-610 and -660W arrays according to standard protocols
[29], as previously described [28]. The results were analyzed for
confirmation of monozygozity for each twin pair and for all
samples from the same subject. The expected values for different
tissues from the same person should be as genotypic concordance
for monozygotic twins (.99.9% identical). We analyzed Illumina
files by Nexus-Copy-Number program (BioDiscovery, CA, USA).
Bioinformatic analysis of the locus between IL10Rb and
IFNAR1 genes
The locus showing variation was analyzed for repeated elements
with the RepeatMasker [30] and tools such as MREPS [31] and
Tandem Repeats Finder [32]. Apart from describing the tandem
repeat sequence, these analyses also defined non-repetitive regions
in this locus that could be used for primer design and definition of
alignment-anchors.
Polymerase chain reaction using genomic DNA
All PCRs were performed in 25 ml reactions comprising 10 ng
gDNA, 0.4 mM each dNTP (Saveen Werner, Sweden), 2 mM
MgCl2 (Invitrogen, Carlsbad, USA), 0.4 mM of primers 1 and 8
(primer 1, 59-CCTAACAGCTGGATAGATTGCC-39 and prim-
er 8, 59-CCATGCGTGTATATTCCATACG-39), 16 PCR
buffer (Invitrogen) and 0.04 U/ml Platinum Taq DNA polymerase
(Invitrogen). Phusion high-fidelity DNA polymerase (New England
BioLabs; cat. No M0530L) was also used according to the
manufacturer’s recommendations. The PCR products were
analyzed on 1% agarose gel.
TA cloning, plasmid purification
For sub-cloning in pCR2.1-TOPO vector (Invitrogen), 2 ml of
PCR product was used. Up to 50 clones per single PCR product
were picked and cultured in LB medium containing 50 mg/ml
kanamycin. The plasmids were purified using QIAprep miniprep
(Qiagen, Hilden, Germany). To confirm the presence of insert,
500 ng of plasmids were digested with EcoRI enzyme (NEB,
Ipswich, USA) and analyzed on 1% agarose gel.
Sanger sequencing
225 ng of plasmid DNA and 1.6 mM sequencing primer were
used in 10 ml reactions with 4 ml BigDyeH Terminator v3.1
(Applied Biosystems, Foster city, USA). Each sequencing reaction
was done in triplicate on ABI 37306l machine. Sequencing
Post-Zygotic Variation in a Presumptive Enhancer
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primers were: primer 2, 59-GAATCGCTTGAACCCGGAAGG-
39; primer 3, 59-CAGGAGAATCGCTTGAAC-39; primer 4, 59-
CCTGGGTAACACAGCGGAAATCC-39; primer 5, 59-
GTTGTGGTGAGCCGAGATCG-39; primer 6, 59-ATACGTA-
TATATTCCATACT-39; primer 7, 59-TATATTCCATACGTA-
TATATT-39; M13 forward, 59-GTAAAACGACGGCCAG-39;
and M13 reverse, 59-CAGGAAACAGCTATGAC-39. Sequences
were aligned and manually inspected using the CodonCode-
Aligner software (http://www.codoncode.com/aligner/index.
htm). We implemented the Phrap-algorithm for accuracy of the
assembly, as recommended for repeat-rich sequences. For a
sequence to enter further analysis, at least one sequence-read had
to go through both of the alignment-anchors (i.e. non-repeated
flanking sequences), to avoid erroneous alignments. After align-
ment the ‘compare contigs’ option in the CodonCode-Aligner was
used to compare the consensus sequences of the identified alleles.
The sequenced alleles are deposited in the GenBank (accession
numbers JQ904024 through JQ904030).
Analysis of tentative enhancer element and CpG islands
We used the Enhancer Element Locator (EEL) computer
program [33] to identify suspected enhancer elements in the locus
between the IL10Rb and IFNAR1 genes. Conserved non-coding
elements (CNEs) were predicted by EEL-program using the
JASPAR CNE matrix profiles [34,35]. This is a collection of 233
matrix profiles from human conserved non-coding elements for
analysis of transcription factor binding sites (TFBS) and enhancer
elements. TOMTOM Motif Comparison Tool was also used in
analysis of the core sequence of the hypervariable region for
similarities with known motifs for transcription factor binding
(http://meme.nbcr.net/meme/cgi-bin/tomtom.cgi) [36]. To an-
alyze the GC-content and predict CpG islands in the region we
used the CPGPLOT-software (http://www.ebi.ac.uk/Tools/
emboss/cpgplot/).
Results
Illumina SNP genotyping suggests a post-zygotic and
inter-individual variation in the locus between IL10Rb
and IFNAR1
We initially genotyped blood DNA from 63 monozygotic (MZ)
twin pairs using Illumina 610 or 660W SNP arrays. Twenty-two
MZ pairs were genotyped using 610 array and 41 MZ pairs were
genotyped using 660W SNP arrays and each MZ pair was treated
as a single case for analysis of post-zygotic variation. Because
nuclear genomes of MZ twins are identical at conception, they
represent a good model for studying post-zygotic variation. The
results were analyzed using Nexus-Copy-Number-Pro-software
and the region between IL10Rb and IFNAR1 genes in 21q22.11
attracted our attention as it showed a frequent variation. Twenty
eight out of 63 MZ twin pairs (44.4%) showed clear-cut differences
in fluorescent intensity signal as measured by Log R ratio (LRR),
either for two consecutive probes on 610-array (cnvi0010759 and
cnvi0010761, at positions of 33615750 bp and 33615748 bp,
respectively) or for two other adjacent probes on 660W-array
(cnvi0065276 and cnvi0066475, at positions 33616087 bp and
33616031 bp, respectively) (Fig. 1). For instance, the two probes
on 610 array indicated deletion in this region in blood DNA of
twin 012_02, when compared to its co-twin and the two probes on
660W SNP array showed deletion in blood DNA of twin 159201,
compared to its co-twin (Fig. 1A and B).
We further expanded our study by 660W-array SNP genotyping
of multiple tissues from 21 patients diagnosed with breast cancer,
where peripheral blood, primary breast tumor, and healthy
morphologically normal breast tissue from the breast affected
with primary tumor were analyzed. Here we counted each patient
as one case for analysis of post-zygotic variation. Clear differences
Figure 1. Indications of post-zygotic copy number variation in
a region between IL10Rb and IFNAR1. Results from eight Illumina
genotyping experiments are shown using blood DNA from two pairs of
monozygotic twins (panel A for twin 012_01 versus co-twin 012_02, and
in panel B for twin 159201 versus co-twin 159202) and two unrelated
individuals, where two different tissues were analyzed from each
subject (Panels C and D; subjects ML36 and SK58, respectively).
Abbreviations BL, PT and UM indicate peripheral blood DNA, primary
breast tumor and healthy morphologically normal breast tissue from a
patient affected with breast cancer, respectively. Illumina 610 or 660W
SNP arrays were used, which also contain so called ‘‘intensity only
probes’’ (often with cvni-prefix), only useful for copy number analyses.
Therefore, only Log R Ratio (LRR) windows of Illumina experiments are
shown here, since the B Allele Frequency (BAF) values are not
informative for this type of probes. LRR values below and above zero
suggest a deletion or a gain, respectively. The four array probes
showing variation between the studied samples are labeled as red dots
in yellow fields.
doi:10.1371/journal.pone.0067752.g001
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in LRR values were observed also in this cohort for two probes
(cnvi0066475 and cnvi0065276) when comparing different tissues
of the same patient in 13 out of 21 cases (61.9%) (Fig. 1C and D).
Thus, in summary for both cohorts of MZ twins and breast cancer
patients, Illumina SNP beadchips suggested a post-zygotic
mosaicism in 41 out of 84 (48.8%) cases, in the locus between
IL10Rb and IFNAR1 genes represented by the four consecutive
array probes. Statistical analysis on this relatively limited sample
size failed to reject the hypothesis of no association between cancer
diagnosis and presence of post-zygotic mosaicism (not shown).
Post-zygotic and inter-individual mosaicism of a
presumptive enhancer embedded in a variable number
of tandem repeats (VNTR)
Application of repeat finding programs on the reference
sequence encompassing locus between the IL10Rb and IFNAR1
genes, revealed that the four above mentioned Illumina probes are
located within a previously not characterized variable number of
tandem repeats (VNTR) (Fig. 2). The NCBI reference sequence
(build 36.3) displayed a 32 bp core motif repeated seven times in
the center of the tandem repeat locus and this core was flanked by
several similar sequence motifs (Fig. 2D, see HVR1098). This
VNTR segment was further embedded in a region very rich in
other types of common repeats (not shown), which made it
challenging to design PCR- and sequencing-primers in the region
around the VNTR segment. The primers that generated reliable
results are shown in Figure 2C. The only primers that
reproducibly generated a PCR product from genomic DNA were
primers 1 and 8.
For the PCR-based validation of array results we selected a
representative series of 17 cases where Illumina results suggested
post-zygotic variation (Table 1, cases 1–17, Fig. 3, 4, 5). These
encompass MZ twin pairs (9 cases) and samples from tissues of
breast cancer patients (8 cases). The list of subjects taken for
validation included also 7 additional samples from unrelated
control subjects, where only one tissue was studied. We
approached validation in this region by PCR amplification from
genomic DNA with primers 1 and 8. This was followed by sub-
cloning of the products into plasmids, preparation of plasmid DNA
from 20–50 bacterial clones for each PCR reaction, analysis of
inserts and Sanger sequencing using the plasmid DNA as template.
It was apparent from the initial PCR reactions with primers 1 and
8 that there was a considerable variation in the length of amplified
fragments. The sequencing was performed using primers 2
through 7 (Fig. 2) as well as with plasmid-based primers, using
all subcloned fragments that were of different size, compared to
the most common allele (see below). The sequence assembly was
performed separately for each subcloned fragment and was guided
by the use of anchor 1 (A1) and anchor 2 (A2) sequences (Fig. 2C
and D), which were non-repetitive and located close to the cassette
of tandem repeat motifs. The Sanger sequencing confirmed the
variation and established nine fully sequenced alleles, with at least
two high-quality forward and reverse sequence reads, showing
sufficient overlap to assure the correct assembly across multiple
similar sequence motifs. These sequences are deposited in the
GenBank database (accession numbers JQ904024 through
JQ904030). We named each of the alleles as HVR (for
hypervariable region), followed by the number of nucleotides in
the sequence between primers 1 and 8. Among the fully sequenced
alleles, the most abundant one (HVR1098, allele frequency
,45%, Fig. 2D) was in agreement with the genome reference
sequence. In addition to HVR1098, we established the full
sequence for five longer alleles (HVR1157, HVR1162, HVR1187,
HVR1219 and HVR1237) and three shorter (HVR1066,
HVR842 and HVR800) (Fig. 2 and Table 1). However, the limits
of current sequencing technology did not permit establishing of the
full-length sequence for the five additional longer HVR alleles
(based on the same stringent quality control of sequence reads that
are aligned between anchors 1 and 2 segments) and their sizes
were therefore estimated from agarose gels (Fig. 5). We also
considered a possibility that the observed variation might be due to
PCR artifacts. We addressed this by using different DNA
polymerase with proof-reading activity. Selected samples (Fig. 5)
were a subject to PCR amplification using (in addition to Taq
polymerase) Phusion high-fidelity DNA polymerase starting from
genomic DNA and the results showed the same pattern of post-
zygotic variation.
It is noteworthy that we validated a relatively high percentage
(10 out of 17; 58.8%) of cases that were suspected to contain post-
zygotic genetic variation in the studied locus from the Illumina
data. When extrapolated to all subjects included in our study,
somatic variation in this VNTR locus is approximately 24%,
which is a high number for a locus displaying post-zygotic
variation, when compared with the literature [17]. We further
calculated the total number of times, for all samples and all cases
combined, that each of the 14 HVR-alleles occurred in our study
(Fig. 4). The most common allele was HVR1098 that was fully
sequenced and was in agreement with NCBI reference sequence.
The second most common was HVR1700 and its full sequence still
remains to be determined. Table 2 shows the summary of all cases,
where Illumina data could be validated. To explain as to why the
validation of Illumina results was unsuccessful for approximately
40% of cases, we analyzed the ‘‘probeA’’-sequences that are used
for synthesis of probes attached to beads and capture of genomic
DNA on Illumina beadchips. Global genome BlastN searches for
similarities of ‘‘probeA’’-sequences for cnvi0010759, cnvi0010761,
cnvi0065276 and cnvi0066475 showed that these are not unique
(not shown), as they match to multiple regions in the human
reference sequence and this is likely the reason for the not fully
predictable behavior during genotyping. We presume that the
results of Illumina copy number genotyping for these ‘‘probeA’’-
sequences is the sum of variation at the HVR region and possible
variation that occurs in other regions of the genome with
similarities to the ‘‘probeA’’-sequences. This implies that the sole
analysis of Illumina beadchip data from these four probes is not a
sufficiently reliable tool for typing of the copy number status within
the HVR in the locus between IL10Rb and IFNAR1. Nevertheless,
it was a good initial tool for variation detection.
The sequence of the segment between IL10Rb and IFNAR1 was
also analyzed using multiple bioinformatic tools for the content of
functional elements important for gene transcription. We identi-
fied features suggesting that the HVR might influence gene
transcription from this locus. The ELL-program found a clustering
of suspected transcription factor binding sites approximately 4 kb
upstream from IFNAR1 transcription start site, suggesting an
enhancer. This presumptive enhancer element was overlapping
with the hypervariable region (Fig. 3) and different alleles had
different number of clusters with binding properties for transcrip-
tion factors. Specifically, EEL program [33] identified similarity
between HVR sequences and CN0062.1 matrix profile [35] with
the consensus sequence 59-AATTGCTTCCAGATG. This 15 bp
sequence motif had 4 mismatches to the core of tandem repeat in
the HVR sequences identified among the nine sequenced alleles.
Using TOMTOM Motif Comparison Tool [36] we further
analyzed 15 bp of our core HVR sequence (59-TATTGGTTC-
CACATA), with or without additions of 5, 7 and 10 bases on both
sides flanking the above sequence. From analyses of Jaspar
database, four transcription factors of Saccharomyces cerevisiae
Post-Zygotic Variation in a Presumptive Enhancer
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(RDR1, HAP2, OPI1 and HSF1) consistently showed the
strongest scores. Results of the best match for the transcription
factor RDR1 (for Repressor of Drug Resistance 1) [37,38] are
shown in Fig. 3I. The RDR1 zinc cluster protein is a member of
Gal4p family of transcriptional regulators and its normal function
in yeast is the transcriptional control of multidrug resistance.
Similar TOMTOM-based analyses of recently published mouse
and human database of transcription factor binding sites [39]
Figure 2. Graphical summary of variation in a presumptive regulatory VNTR containing region. Panel A shows an overview of
approximately 2 Mb locus on 21q, around four genes encoding functionally related receptors; IFNAR2, IL10Rb, IFNAR1 and IFNGR2. Panel B is zooming
on the position of the hypervariable region (HVR, red box), which is located approximately 4 kb upstream from the transcription start site of the
IFNAR1 gene and is flanked by CpG-islands (green boxes). The last three and the first three exons of IL10Rb, and IFNAR1, respectively, are shown as
grey boxes. Panel C is showing the size and position of HVR according to the most common allele (HVR1098, see below panel D) in relation to the
CpG island. Positions of PCR and sequencing primers used in the analysis of the locus are also displayed. Yellow boxes indicate the position of the
non-repetitive anchor 1 (A1) and anchor 2 (A2) sequences, that are immediately flanking the repeated segments and were used for alignments of
sequence reads. Panel D shows a summary of eight HVR-alleles from the studied samples, which were identified based on Sanger sequencing results
of PCR fragments sub-cloned in plasmids. The displayed alleles are ordered from longest to shortest according to size from anchor 1 (A1) to anchor 2
(A2) sequences. Summary of sizes for all 14 different HVR-alleles is shown in Table 1. Sizes of fragments (in base pairs) are given between non-
repetitive A1 and A2 sequences and between primers p1 and p8, which were used for PCR amplification from genomic DNA. Asterisk (*) indicates the
most frequent allele (HVR1098), which is in agreement with the reference sequence according to NCBI sequence build 36.3. The allele frequency
shown here is taking into account only the nine alleles, where the entire sequence could be unequivocally determined using Sanger sequencing. The
most common variation encompasses the variable number of 32 base pair segments; i.e. indel 2, indel 3, indel 4, and indel 5. The latter indel 5 is
composed of 6 repeated 32 base pair segments (HVR1066). However, there are also indels containing shorther segments; e.g. indel 1, indel 6 and
indel 7. Panel E illustrates the positions of two of the four probes from Illumina beadchips, which are aligned onto the NCBI reference sequence for
this locus (top sequence with an asterisk, representing HVR1098). The two probes shown here are from Illumina 610 SNP array; cnvi0010761 (green)
and cnvi0010759 (blue). All four Illumina probes from Figure 1, which were used for initial identification of variation in this region are located within
hypervariable region. As shown here for two of these four probes, the probeA sequences (as called by Illumina and used for capturing of genomic
DNA on beadchips) are shifted only by two bases. The core 32 bp repeat motif is shown in brackets.
doi:10.1371/journal.pone.0067752.g002
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revealed strongest match to the mouse transcription factor Foxg1
binding motif (Fig. 3J). Forkhead-box (FOX) family of transcription
factors represent a large group of proteins with crucial roles in
development and metabolism, which were studied in many species.
The human genome encodes 43 FOX proteins [40,41,42]. The
FOXG1 is crucial for normal brain development [43] and loss-of-
function mutations in FOXG1 cause an atypical form of Rett
syndrome [44]. On the other hand, overexpression of FOXG1 is
implicated in cancer development [45,46]. In summary, the motif
analyses suggest that the HVR locus might function as an enhancer
but we have not unambiguously identified its protein binding
partners. Further studied are needed to address this question.
Furthermore, mining of the ENCODE dataset [1] (http://
genome.ucsc.edu/ENCODE/) supported a role for the 1.45 kb
region (displayed in Fig. 2C) as a suspected enhancer element (Fig.
S1). The ChIP-seq ENCODE data was used, in combination with
the ChromHMM and Segway programs to perform the
segmentations in six cell lines. Results from three cell lines
(GM12878, HeLa-S3 and HepG2) were consistent with enhancer
predictions. In agreement with the above, ENCODE data tracks
representing the set of open chromatin elements and signals based
on DNase-seq results suggest multiple DNaseI hypersensitivity
clusters in CD20+ cells and four additional cell lines (Fig. S1).
Analyses also showed the presence of a CpG island just upstream
Figure 3. Analysis of the transcription factor binding sites (TFBSs) for the sequenced HVR-alleles. Panel A shows graphical
representation of the most frequently occurring allele in our data set (HVR1098) with identical distribution of in-dels as compared to the NCBI
reference genome build 36.3 (see also Fig. 2B–D). The HVR region is flanked by the non-repetitive sequences referred to as anchor A1 and A2 (yellow
boxes) that were used for alignment of sequence reads. Green box illustrates the position of a CpG island and the overall layout of this figure is
analogous to Fig. 2. Analysis using the EEL-software (Enhancer Element Locator [33]) of ,1.2 kb of the NCBI reference sequence upstream from the
transcription start site of the IFNAR1 gene on chromosome 21, showing a clustering of TFBSs in the core of the HVR. Grey boxes indicate the positions
of the predicted TFBSs in the region and they were determined by the CN0062.1 matrix profile (from ref. [35]) with the consensus sequence 59-
AATTGCTTCCAGATG. Panels B–H show the predicted TFBSs in sequenced alleles HVR1219, HVR1187, HVR1162, HVR1157, HVR1098, HVR1066 and
HVR842, identified using the matrix profile CN0062.1. Panel I shows results of the best match for Saccharomyces cerevisiae transcription factor RDR1
(for Repressor of Drug Resistance 1) with TOMTOM Motif Comparison Tool [36]. Panel J illustrates TOMTOM-based analyses of mouse and human
database of transcription factor binding sites [39], which revealed the best match to the mouse transcription factor Foxg1 binding motif.
doi:10.1371/journal.pone.0067752.g003
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the predicted enhancer element (Figs. 2 and 3). Thus, in summary,
the above observations suggest a functional gene-regulatory role of
the studied locus and that the VNTR we describe should be
studied further for functional consequences on gene transcription.
Discussion
Post-zygotic variation has been estimated to ,1% in young
subjects routinely analyzed in the course of genetic counseling
[47]. Our recent analyzes in population-based aging cohort
showed that ,3.5% of people older than 60 years carry mega-base
range post-zygotic rearrangements [28]. Our current results
suggest that the VNTR locus studied here has a considerably
higher rate of post-zygotic variation, as ,24% of cases in this
study have been estimated to display post-zygotic differences.
Furthermore, this number is likely an underestimate, as a limited
number of specimens from different tissues were studied for each
case. These results are in agreement with the estimates suggesting
that de novo mutation rate for VNTRs is higher than the
corresponding rates for other types of structural rearrangements
[2]. The inter-individual copy number variation in the VNTR
locus studied here has been noticed previously, but was not
explored in detail [14] (supplemental data; locus ID CNVR7995).
Conrad et al. 2010 applied two variation detection methods; first
was Nimblegen genotyping on 42M genome-wide tiling-path
array. Results from this array were validated by 105K Agilent
array designed to target the variable loci only. The CNVR7995 in
Conrad et al. is one among 8599 inter-individually variable loci.
Although CNVR7995 was shown variable among different people,
it could not be unambiguously genotyped by further array-CGH
experiments using 450 subjects; i.e. placed in a one class of
genotypes such as heterozygous deletion, diploid state, gain of one
(or more) copies and was therefore not included in the final list of
5238 validated and genotyped loci. A possible reason behind the
failure in this last step could be the post-zygotic variation in
CNVR7995; i.e. DNA samples studied contained a mixture of
genotypes and were not possible to score unambiguously. The
intriguing question emerging from the above reasoning is: Are the
remaining loci (39%, 3360 loci that could not be unambiguously
genotyped on the final validation platform in Conrad et al. 2010)
also showing post-zygotic variation?
One of the first described and well-studied VNTR-based
enhancers in the human genome is located upstream of the
human insulin gene (INS) on chromosome 11p15. This VNTR has
been shown to regulate not only the expression of the closest gene
(INS), but also the IGF2 gene, located downstream on the same
DNA strand from INS, thus demonstrating the long range effect of
the VNTR on gene transcription [12,48]. The field of DNA
enhancers provides additional examples regarding a capacity of
the enhancers to exert their regulatory effects on genes located at
large genomic distances. Enhancers can activate gene expression
independent of their orientation and are commonly scattered
across noncoding intervals, in extreme cases functioning at a
distance of .1 Mb from their gene promoter target [13,49]. The
VNTR upstream of the INS gene has also attracted a considerable
interest in medical genetics, as its length has been associated with
type 1 and type 2 diabetes, latent autoimmune diabetes in adults
(LADA), polycystic ovary syndrome as well as with size at birth
[50,51,52,53,54].
The region around the presumptive enhancer studied here
(Fig. 2) contains four functionally related receptor genes: interferon
alpha, beta and omega receptor 2 (IFNAR2); interleukin 10
receptor beta (IL10Rb); interferon alpha, beta and omega receptor
1 (IFNAR1); and interferon gamma receptor 2 (IFNGR2).
Considering the above discussed regulatory functions for VNTR
upstream of the INS gene and other well studied enhancers, it is
reasonable to hypothesize that this tentative VNTR-based
enhancer located between IL10Rb and IFNAR1 genes might be
involved in regulation of transcription of not only IFNAR1 gene,
but also additional genes located in its vicinity. This issue is an
important subject for future studies. There exists an extensive
literature describing physiological functions for these interferon/
Figure 4. The frequency distribution of the 14 alleles identified for the hypervariable region. The white bars represent alleles defined by
both agarose gels and Sanger sequencing. The grey bars denote alleles that were characterized by estimation of their sizes from agarose gels. All
alleles were defined based on the analysis between primers 1 and 8 (see Fig. 2 and Table 1).
doi:10.1371/journal.pone.0067752.g004
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cytokine receptor pathways and their involvement in disease-
related processes [55,56,57,58,59]. For instance, type-I interferon
(IFN-alpha)-induced signaling was reduced in T cells and B cells
from 3 major groups of cancer patients (breast cancer, melanoma,
and gastrointestinal cancer) compared to healthy controls. Type-II
interferon (IFN-gamma)-induced signaling was also reduced in B
cells from these cancer patient groups. These findings suggest that
defects in lymphocyte IFN signaling arise in patients with common
cancers, and these defects may represent a common cancer-
associated mechanism of immune dysfunction [56]. Interferon
alpha is also implicated in the autoimmune disease such as
systemic lupus erythematosus, where there is a continuous
overproduction of IFN-alpha and increased expression of IFN-
alpha-regulated genes [60].
Conclusions
This study shows post-zygotic genetic variation in a VNTR-
locus, which has sequence properties of an enhancer. This
variation may affect the expression of gene(s) that are under the
control of this regulatory element and understanding the
phenotypic consequences of both post-zygotic and inter-individual
Figure 5. Variable length of alleles within hypervariable region showing post-zygotic variation. Panel A shows post-zygotic mosaicism
in healthy and phenotypically concordant monozygotic twin pair 148341/148342, with five alleles observed in twin 148341, and three alleles present
in co-twin 148342. Similarly, panel B displays post-zygotic variation in another monozygotic twin pair 004_01/004_02. In total 5 different alleles are
shown on this gel and only one of them is overlapping between both twins. Panel C illustrates post-zygotic mosaicism in breast cancer patient SK58.
There are three different alleles in DNA from morphologically normal breast tissue (UM), two alleles in blood cells (BL) and three alleles in primary
tumor (PT). In panels A, B and C, Taq DNA polymerase was used for initial PCR amplification from genomic DNA, as indicated by suffix ‘‘T’’ in the ID of
each plasmid clone. In panel D, Phusion DNA polymerase confirmed post-zygotic mosaicism in monozygotic twin pair 148341/148342, as indicated
by suffix ‘‘Ph’’ in the ID of each plasmid clone. The length of inserts in all plasmid clones was estimated after EcoRI digestion releasing the insert, and
using 1% agarose gel. BL, PT and UM indicate peripheral blood DNA, primary breast tumor and healthy morphologically normal breast tissue from a
patient affected with breast cancer, respectively.
doi:10.1371/journal.pone.0067752.g005
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variation within this enhancer on the level of single cell and whole
organism is a task for future work. Our findings of post-zygotic
genetic variation add another level of complexity to the genetic
variation among VNTR loci in general and in particular to the
possible phenotypic consequences of variation in the VNTR-locus
between IL10Rb and IFNAR1 genes. This VNTR-based presump-
tive enhancer is within a locus containing four functionally related
cytokine receptor genes; IFNAR2, IL10Rb, IFNAR1 and IFNGR2.
We hypothesize that this element might function in transcriptional
regulation of not only the closest IFNAR1 gene, but also other
flanking genes. The extension of our work may unveil the normal
function of this VNTR-locus in transcriptional control of genes.
Furthermore, our work opens up for studies of associations of
length of VNTR alleles in cohorts of patients with various immune
system dysfunctions, for instance autoimmune disorders or cancer.
Interferons, acting via multiple receptor genes encoded from the
locus studied here, are already used in clinical treatment of
patients with various conditions. Our study may also be a starting
point for analysis aiming at understanding of why there often is a
variable response to treatment with interferons.
Supporting Information
Figure S1 The results from mining of the Encode
project dataset (http://genome.ucsc.edu/ENCODE/).
Panel A shows ,13 kb segment centered on HVR with co-
ordinates chr21:34687376-34700434 (build 37/hg19) and
chr21:33609246-33622304, acc. to build 36/hg18. On the right
hand side, this view also includes the promoter/cis-regulatory
elements and exon 1 of the IFNAR1 gene. The three colored solid
horizontal bars show results (in compressed view) from the ChIP-
seq experiments in six cell lines. These were analyzed by a
combination of the ChromHMM and Segway programs to perform
the segmentations. Three cell lines (GM12878, HeLa-S3 and
HepG2) showed ‘‘predicted weak enhancer or open chromatin cis
regulatory element’’ in yellow. Other color codes indicate: bright
red, predicted promoter region including transcription start site;
light red, predicted promoter flanking region; dark green, predicted
transcribed region; gray, predicted repressed or low activity region;
light green, low activity region. Results from ENCODE data tracks
representing the open chromatin signals based on DNase-seq
experiments are shown below. Light blue bars indicate DNaseI
hypersensitivity clusters in CD20+ cells, GM18507 cells, HA-sp
cells, HCFaa cells and HCM cells. Panel B illustrates ENCODE
data in greater detail for a segment of 1.45 kb, which corresponds to
the region displayed in Fig. 2C (chr21:34693180-34694630, build
37/hg19; and chr21:33615050-33616500, build 36/hg18). The
results from ChIP-seq experiments and data tracks representing the
open chromatin signals based on DNase-seq experiments are shown
in expanded view. The color codes for different predictions are the
same as described above for panel A.
(TIF)
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Table 2. Summary of validation of somatic variation in the IFNAR1 locus.
Subject ID Analysed tissues
Mosaicism indicated by
Illumina platform? Illumina results verified? Validation method
SK58* BL, UM, PT Yes Yes Gel+Seq
ML36* BL, UM, PT Yes Yes Gel+Seq
KJ42* BL, UM Yes No Gel+Seq
NM48* BL, UM, PT Yes No Gel+Seq
KU25* BL, UM, PT Yes No Gel+Seq
PF27* BL, UM, PT Yes No Gel+Seq
JM43* BL, UM, PT Yes No Gel+Seq
PK6* BL, UM, PT Yes No Gel+Seq
004_01/004_02** BL Yes Yes Gel+Seq
159201/159202** BL Yes Yes Gel+Seq
21801/21802** BL Yes Yes Gel+Seq
183411A/183412A** BL Yes Yes Gel
148341/148342** BL Yes Yes Gel+Seq
169101A/169102A** BL Yes Yes Gel
188831/188832** BL Yes Yes Gel
2123411/2123412** BL Yes Yes Gel+Seq
030_01/030_02** BL Yes No Gel+Seq
Summary of Illumina SNP genotyping, which suggested structural variation within the hypevariable region and results from subsequent confirmation using Sanger
sequencing and agarose gel electrophoresis. One (*) and two (**) asterisks after the subject ID indicate patients with breast cancer and pairs of monozygotic twins,
respectively. BL, UM and PT stand for DNA from peripheral blood cells, healthy morphologically normal breast tissue from a patient affected with breast cancer and
primary breast tumor, respectively. ‘‘Seq’’ indicate that the somatic mosaicism was verified by Sanger sequencing while ‘‘Gel’’ shows that it was confirmed by estimation
of allele sizes from agarose gel.
doi:10.1371/journal.pone.0067752.t002
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